-
Signature
-
/s/ Bruce Jacobs, as Attorney-in-Fact
-
Stock symbol
-
KYMR
-
Transactions as of
-
Oct 13, 2025
-
Transactions value $
-
-$184,392
-
Form type
-
4
-
Date filed
-
10/14/2025, 05:11 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Gollob Jared |
Chief Medical Officer |
C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN |
/s/ Bruce Jacobs, as Attorney-in-Fact |
2025-10-14 |
0001821198 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
KYMR |
Common Stock |
Options Exercise |
$1.05K |
+800 |
+0.67% |
$1.31 |
121K |
Oct 13, 2025 |
Direct |
F1 |
| transaction |
KYMR |
Common Stock |
Options Exercise |
$1.4K |
+673 |
+0.56% |
$2.08 |
121K |
Oct 13, 2025 |
Direct |
F1 |
| transaction |
KYMR |
Common Stock |
Sale |
-$187K |
-3.11K |
-2.56% |
$60.00 |
118K |
Oct 13, 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
KYMR |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-800 |
-2.68% |
$0.00 |
29K |
Oct 13, 2025 |
Common Stock |
800 |
$1.31 |
Direct |
F1, F2 |
| transaction |
KYMR |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-673 |
-2.94% |
$0.00 |
22.2K |
Oct 13, 2025 |
Common Stock |
673 |
$2.08 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: